Progestins and menopause: Epidemiological studies of risks of endometrial and breast cancer

Steroids

Volumn 65, Issue 10-11, 2000, Pages 659-664

  Pike, Malcolm C ^a   Ross, Ronald K ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Breast cancer; Endometrial cancer; Hormone replacement therapy; Progestins

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; PROGESTERONE;

ANOVULATION; BREAST CARCINOMA; CANCER RISK; CARCINOGENESIS; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG TISSUE LEVEL; DRUG TOLERANCE; ENDOMETRIUM CARCINOMA; ESTROGEN THERAPY; FEMALE; GESTAGEN BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; OBESITY; PRESCRIPTION; PROGESTERONE BLOOD LEVEL; RISK ASSESSMENT;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; PROGESTINS; RISK FACTORS; URBAN POPULATION;

EID: 0033668796     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(00)00122-7     Document Type: Conference Paper

References (35)

1. Hormone replacement therapy and endometrial cancer risk: A meta-analysis
2. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: Its central role in explaining and predicting endometrial cancer risk
3. The prevention and treatment of endometrial pathology in postmenopausal women receiving exogenous estrogens
4. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk
5. Estrogen-progestin replacement therapy and endometrial cancer
6. Estrogen versus estrogen-progestogen hormone replacement therapy: Effect on breast cancer risk
7. Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk
8. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: Results of a prospective study
9. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer
10. Estrogen replacement therapy and endometrial cancer risk: Unresolved issues
11. Estrogens, progesterone, and endometrial cancer
12. Combined estrogen and progesterone use and endometrial cancer
13. Risk of endometrial cancer in relation to use of oestrogen combined with progestagen therapy in postmenopausal women
14. Progestin action in relation to the prevention of endometrial abnormalities
15. Is Provera the ideal progestogen for addition to postmenopausal estrogen therapy?
16. Mechanisms of uterine bleeding in postmenopausal patients receiving estrogen alone or with a progestin
17. Endometrial disease after treatment with oestrogens and progestogens in the climacteric
18. Age-related factors in cancers of the breast, ovary, and endometrium
19. Cyclic hormone replacement therapy using quarterly progestin
20. Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement
21. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer
22. The relationship of exogenous hormones to breast cancer risk
23. Breast cancer and hormone replacement therapy
24. Combined oestrogen-progestogen replacement therapy and breast cancer risk
25. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
26. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy
27. Mammographic parenchymal patterns and breast cancer risk
28. Effects of estrogen and estrogen-progestin on mammographic parenchymal density
29. Regulation of progesterone receptor messenger ribonucleic acid and protein levels in MCF-7 cells by estradiol: Analysis of estrogen's effect on progesterone receptor synthesis and degradation
30. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular (i.m.) and vaginal routes: A comparative study
31. Transvaginal administration of progesterone
32. Prevention of endometrial hyperplasia in postmenopausal women with intrauterine progesterone
33. Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy
34. Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement
35. Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy